An Open Label, Dose Escalation Study Evaluating the Safety and Pharmacokinetics of SAR245408 Administered Orally Daily in Patients With Solid Tumors.

Trial Profile

An Open Label, Dose Escalation Study Evaluating the Safety and Pharmacokinetics of SAR245408 Administered Orally Daily in Patients With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2014

At a glance

  • Drugs Pilaralisib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 02 Dec 2014 Status changed from active, no longer recruiting to completed, according ClinicalTrials.gov record.
    • 19 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.
    • 18 Apr 2013 Planned End Date changed from 1 Jan 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top